Sexually transmitted infection

Lizzo’s ‘Truth Hurts’ the Inspiration for AHF’s Condom Day Music Video

Retrieved on: 
Wednesday, February 12, 2020
Online, Events, Concerts, Other Policy Issues, Healthcare reform, General Entertainment, Women, Infectious diseases, Teens, Public policy, Government, Music, MEN, Gay & Lesbian, Entertainment, AIDS, Consumer, Health, RTT, HIV/AIDS, Sexual health, Medical specialties, Condom, Penis, Female condom, Health, Sexually transmitted infection, Human reproduction

These events include five higher profile and free Safer is Sexy burlesque shows in the U.S. (L.A., Washington, DC ; New York , Atlanta and Ft Lauderdale).

Key Points: 
  • These events include five higher profile and free Safer is Sexy burlesque shows in the U.S. (L.A., Washington, DC ; New York , Atlanta and Ft Lauderdale).
  • This year, the musical target was current cultural phenom Lizzo and her runaway blockbuster, Truth Hurts, which was retitled and repurposed for International Condom Day as Safer Works.
  • for Condom Day, a song that so far reached nearly 900,000 viewers on YouTube.
  • International Condom Day, created by AHF and celebrated each year on February 13th (the day before Valentines Day), came about as an innovative and lighthearted way to remind people that wearing a condom can prevent pregnancy and STDs, including HIV.

AHF Hosts International Condom Day Events to Promote Safer Sex

Retrieved on: 
Wednesday, February 5, 2020
AIDS, Health, Philanthropy, General Health, Other Policy Issues, General Entertainment, Events, Concerts, Entertainment, Infectious diseases, Foundation, Public policy, Government, Medical specialties, Health, HIV/AIDS, Articles, RTT, Sexual health, AIDS Healthcare Foundation, Condom, AHF, Female condom, Sexually transmitted infection, Safe sex

AIDS Healthcare Foundation (AHF), the largest non-profit HIV/AIDS organization in the world, operating in 44 countries, again celebrates International Condom Day (ICD) on February 13th.

Key Points: 
  • AIDS Healthcare Foundation (AHF), the largest non-profit HIV/AIDS organization in the world, operating in 44 countries, again celebrates International Condom Day (ICD) on February 13th.
  • View the full release here: https://www.businesswire.com/news/home/20200205005880/en/
    AHF is putting sexy back in safer sex.
  • International Condom Day, created by AHF and celebrated each year on February 13th (the day before Valentines Day), came about as an innovative and lighthearted way to remind people that wearing a condom can prevent pregnancy and STDs, including HIV.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us @aidshealthcare .

2020 Europe Sexually-Transmitted Disease Testing Market - Chancroid, Chlamydia, Gonorrhea, Herpes, HPV & Syphilis - ResearchAndMarkets.com

Retrieved on: 
Monday, January 27, 2020
Health, Infectious diseases, RTT, Sexually transmitted diseases and infections, Medical specialties, Infectious causes of cancer, Health, Medicine, Sexually transmitted infection, Gonorrhea, Chancroid, Chlamydia, Human papillomavirus infection, Sexual health clinic

The "2020 Europe Sexually-Transmitted Disease (STD) Testing Market: France, Germany, Italy, Spain, UK - Supplier Shares and Sales Segment Forecasts - Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2020 Europe Sexually-Transmitted Disease (STD) Testing Market: France, Germany, Italy, Spain, UK - Supplier Shares and Sales Segment Forecasts - Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis" report has been added to ResearchAndMarkets.com's offering.
  • This new 318-page report from the author provides analysis of the European sexually-transmitted disease testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers.
  • The report presents detailed analysis of the STD market in Europe (France, Germany, Italy, Spain, UK), Current scientific views on epidemiology and etiology are presented for Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, and Syphilis.
  • Examines market applications of Molecular Diagnostics, Monoclonal Antibodies, Immunoassays, IT and other emerging technologies

Global Sexually Transmitted Disease Testing Market 2020: Supplier Shares & Sales Segment Forecasts by Country - ResearchAndMarkets.com

Retrieved on: 
Friday, January 24, 2020
Health, Infectious diseases, Medical specialties, RTT, Sexually transmitted diseases and infections, Medicine, Health, Infectious causes of cancer, Infections with a predominantly sexual mode of transmission, Mycoplasma, Sexually transmitted infection, Chlamydia, Chancroid, Gonorrhea

The "2020 Global Sexually Transmitted Disease (STD) Testing Market: US, Europe, Japan - Supplier Shares and Sales Segment Forecasts by Country - Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2020 Global Sexually Transmitted Disease (STD) Testing Market: US, Europe, Japan - Supplier Shares and Sales Segment Forecasts by Country - Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis" report has been added to ResearchAndMarkets.com's offering.
  • This new 350-page report from the author contains 90 tables and provides analysis of the global sexually transmitted disease testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers.
  • The report presents detailed analysis of the STD market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan.
  • The report provides test volume and sales forecasts by country and market segment, including:
    In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of STD diagnostic products, by test and country.

Global Condom Market 2020-2024 | Evolving Opportunities with Church & Dwight Co. Inc. & Cupid Ltd. | Technavio

Retrieved on: 
Wednesday, January 8, 2020
Women, Other Retail, Consumer, Retail, MEN, RTT, HIV/AIDS, Sexual health, Medical specialties, Barrier contraception, Female condom, Condom, Sexually transmitted infection, Health, Human reproduction

View the full release here: https://www.businesswire.com/news/home/20200108005513/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200108005513/en/
    Technavio has announced its latest market research report titled global condom market 2020-2024.
  • The market is driven by the increasing prevalence of sexually transmitted diseases.
  • Also, the increasing popularity of female condoms is anticipated to further boost the growth of the condom market.
  • Church & Dwight Co. Inc. has business operations under various segments, which include consumer domestic, consumer international, and specialty products division.

Global Sexually Transmitted Disease (STD) Testing Market 2019-2023 | Evolving Opportunities with Abbott Laboratories and bioMérieux SA | Technavio

Retrieved on: 
Saturday, December 14, 2019
Infectious diseases, General Health, AIDS, Health, Mycoplasma, RTT, Sexually transmitted infection, STD

View the full release here: https://www.businesswire.com/news/home/20191213005433/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20191213005433/en/
    Technavio has announced its latest market research report titled global sexually transmitted disease testing market 2019-2023.
  • (Graphic: Business Wire)
    The market research report segments the sexually transmitted disease (STD) testing market by product (laboratory testing devices and point of care (POC) testing devices) and geography (Asia, Europe, North America, and ROW).
  • Sexually Transmitted Disease (STD) Product Outlook (Revenue, USD Billion, 2019-2023)
    The market will witness significant demand for laboratory testing devices over the forecast period.
  • Technavio's SUBSCRIPTION platform
    Major Five Sexually Transmitted Disease Testing Companies:
    Abbott Laboratories, bioMrieux SA, Bio-Rad Laboratories Inc., Danaher Corp., and F. Hoffmann-La Roche Ltd. are among the vendors who have a strong position in the global market.

Global Infectious Disease In Vitro Diagnostic (IVD) and Molecular Test Market Report 2019-2023 with Coverage of Roche, Abbott Laboratories, BioMrieux, Siemens Healthineers

Retrieved on: 
Tuesday, December 3, 2019
Medicine, RTT, Medical specialties, Health, Epidemiology, Infectious diseases, Actuarial science, Disease, Medical terminology, Infection, Sexually transmitted infection, Infectious disease

3.1 Global Infectious Disease In Vitro Diagnostic (IVD) Market: An Analysis

Key Points: 
  • 3.1 Global Infectious Disease In Vitro Diagnostic (IVD) Market: An Analysis
    3.1.2 Global Infectious Disease In Vitro Diagnostic (IVD) Market by Type (Immunoassays, Molecular Test, and Traditional Microbiology)
    3.1.3 Global Infectious Disease In Vitro Diagnostic (IVD) Market by Region (The US, Western Europe, Australia, and ROW)
    3.2 Global Infectious Disease In Vitro Diagnostic (IVD) Market: Type Analysis
    3.2.3 Global Infectious Disease Molecular Test Market by Infection (Sexually Transmitted Infections (STIs), ESBL & CPO, Enteric, Respiratory (Influenza & RSV), and Other Infections)
    3.2.5 Global Infectious Disease Molecular Test Market by Region (The US, Western Europe, Australia, and ROW)
    3.3 Global Infectious Disease Molecular Test Market: Infection Analysis
    3.4 Global Infectious Disease Molecular Test Market: End-use Analysis
    4.1 The US Infectious Disease In Vitro Diagnostic (IVD) Market: An Analysis
    4.1.4 The US Infectious Disease Molecular Test Market by Infection (Sexually Transmitted Infections (STIs), Respiratory (Influenza & RSV), Enteric, Flavivirus/Alphavirus, ESBL & CPO, and Other Infections)
    4.2 Western Europe Infectious Disease In Vitro Diagnostic (IVD) Market: An Analysis
    4.3 Australia Infectious Disease In Vitro Diagnostic (IVD) Market: An Analysis
    4.4 ROW Infectious Disease In Vitro Diagnostic (IVD) Market: An Analysis

Global Infectious Disease In Vitro Diagnostic (IVD) and Molecular Test Market Size, Trends and Forecasts Report 2019-2023 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 2, 2019
Infectious diseases, Health, Medical devices, Medicine, RTT, Medical specialties, Health, Epidemiology, Infectious diseases, Actuarial science, Disease, Medical terminology, Infection, Sexually transmitted infection, Infectious disease

3.1 Global Infectious Disease In Vitro Diagnostic (IVD) Market: An Analysis

Key Points: 
  • 3.1 Global Infectious Disease In Vitro Diagnostic (IVD) Market: An Analysis
    3.1.2 Global Infectious Disease In Vitro Diagnostic (IVD) Market by Type (Immunoassays, Molecular Test, and Traditional Microbiology)
    3.1.3 Global Infectious Disease In Vitro Diagnostic (IVD) Market by Region (The US, Western Europe, Australia, and ROW)
    3.2 Global Infectious Disease In Vitro Diagnostic (IVD) Market: Type Analysis
    3.2.3 Global Infectious Disease Molecular Test Market by Infection (Sexually Transmitted Infections (STIs), ESBL & CPO, Enteric, Respiratory (Influenza & RSV), and Other Infections)
    3.2.5 Global Infectious Disease Molecular Test Market by Region (The US, Western Europe, Australia, and ROW)
    3.3 Global Infectious Disease Molecular Test Market: Infection Analysis
    3.4 Global Infectious Disease Molecular Test Market: End-use Analysis
    4.1 The US Infectious Disease In Vitro Diagnostic (IVD) Market: An Analysis
    4.1.4 The US Infectious Disease Molecular Test Market by Infection (Sexually Transmitted Infections (STIs), Respiratory (Influenza & RSV), Enteric, Flavivirus/Alphavirus, ESBL & CPO, and Other Infections)
    4.2 Western Europe Infectious Disease In Vitro Diagnostic (IVD) Market: An Analysis
    4.3 Australia Infectious Disease In Vitro Diagnostic (IVD) Market: An Analysis
    4.4 ROW Infectious Disease In Vitro Diagnostic (IVD) Market: An Analysis

Evofem Biosciences Reports Positive Top-Line Results from Phase 2b Study of Amphora® for Prevention of Chlamydia and Gonorrhea in Women

Retrieved on: 
Monday, December 2, 2019
Sexually transmitted diseases and infections, Infectious causes of cancer, Medical specialties, Chlamydiae, Infectious diseases, RTT, Infections with a predominantly sexual mode of transmission, Medicine, Chlamydia, Gonorrhea, Sexually transmitted infection, Neisseria gonorrhoeae

AMPREVENCE is a double-blinded, placebo-controlled Phase 2b clinical trial that enrolled 860 women who had been treated for chlamydia or gonorrhea in the four months prior to enrolling in the study.

Key Points: 
  • AMPREVENCE is a double-blinded, placebo-controlled Phase 2b clinical trial that enrolled 860 women who had been treated for chlamydia or gonorrhea in the four months prior to enrolling in the study.
  • The primary and secondary endpoints of the study were the prevention of acquisition of urogenital Chlamydia trachomatis and Neisseria gonorrhea, respectively.
  • Evofem Biosciences aims to advance the lives of women by developing innovative solutions, such as woman-controlled contraception and potential protection from certain sexually transmitted infections (STIs).
  • Amphora is a registered trademark and MVP-R is a trademark of Evofem Biosciences, Inc.

Newly Published Research Demonstrates Ability of Hologic’s Assay to Detect Mycoplasma Genitalium, “the Silent Epidemic”

Retrieved on: 
Monday, November 11, 2019
Health, Infectious diseases, General Health, Research, Science, Biotechnology, Infectious causes of cancer, Sexually transmitted diseases and infections, Biostatistics, Natural sciences, Organisms, Physical sciences, Synthetic biology, Mycoplasma genitalium, Assay, Mycoplasma, Positive and negative predictive values, Sexually transmitted infection

A newly published study demonstrates clinical evidence for the effectiveness of a first-of-its-kind, FDA-cleared assay for the detection of the sexually transmitted bacterium Mycoplasma genitalium (M. genitalium).

Key Points: 
  • A newly published study demonstrates clinical evidence for the effectiveness of a first-of-its-kind, FDA-cleared assay for the detection of the sexually transmitted bacterium Mycoplasma genitalium (M. genitalium).
  • Subjects were enrolled at STI clinics, clinical research centers, and emergency medicine, family planning, public health, STI and family medicine/obstetric-gynecologic sites.
  • The study evaluated prevalence, sensitivity, specificity, positive predictive value, and negative predictive value for the Aptima assay compared to a composite molecular reference standard.
  • Results showed that for each of seven specimen types, Aptima assay results aligned closely with results obtained with the composite reference standard.